Nav1.7 is a voltage-gated sodium-channel alpha subunit encoded by SCN9A. It is highly expressed in nociceptive dorsal-root-ganglion neurons and other peripheral sensory compartments, where it acts as a threshold amplifier for action-potential initiation.[1][2] Human genetics established Nav1.7 as one of the clearest causal pain targets in medicine: loss-of-function variants cause congenital insensitivity to pain, while gain-of-function variants drive severe pain syndromes such as inherited erythromelalgia and related channelopathies.[3][4]
Because of this unusually strong genotype-phenotype validation, Nav1.7 remains a major non-opioid analgesic target and a benchmark model for precision ion-channel therapeutics.[1:1][5][6]
Nav1.7 follows the canonical Nav architecture (four homologous domains with six transmembrane segments each), with voltage sensing in S1-S4 and pore/selectivity modules in S5-S6.[2:1] Cryo-EM structures of human Nav1.7 in complex with auxiliary subunits and toxins provided high-resolution templates for rational inhibitor design and state-dependent ligand development.[2:2]
Biophysically, Nav1.7 is positioned to amplify small depolarizations toward firing threshold. This “gain control” behavior explains why modest kinetic shifts can yield major pain phenotypes in patients with pathogenic SCN9A variants.[3:1][4:1]
Key roles include:
In translational terms, Nav1.7 is attractive because it is comparatively peripheral-dominant relative to many CNS sodium channels, offering a plausible route to analgesia with fewer central adverse effects when selectivity is sufficient.[1:2][5:2]
Nav1.7 sits at the center of a continuum from pain loss to pain amplification:
Nav1.7 is not a primary monogenic driver of Alzheimer's disease or Parkinson's disease, but it is clinically relevant in neurodegeneration-adjacent domains:
Despite very strong target genetics, clinical translation has been difficult, mainly due to selectivity constraints versus other Nav isoforms and the complexity of state-dependent blockade in human pain circuits.[1:4][5:4][6:2]
Current strategy themes include:
Recent trial-focused reviews indicate continued activity in Nav1.7 programs with improving structure-guided medicinal chemistry, but emphasize the gap between strong target rationale and consistently robust clinical efficacy signals.[6:4]
For NeuroWiki ranking workflows, Nav1.7 is a high-confidence “causal target” in pain biology but a context-dependent target in neurodegeneration. Evidence should therefore be interpreted as:
Emery EC et al. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opinion on Therapeutic Targets. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Shen H et al. Structures of human Na(v)1.7 channel in complex with auxiliary subunits and animal toxins. Science. 2019. ↩︎ ↩︎ ↩︎
Cox JJ et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006. ↩︎ ↩︎ ↩︎ ↩︎
Zhang Z et al. Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia. Scandinavian Journal of Pain. 2014. ↩︎ ↩︎ ↩︎
Xue Y et al. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models. Neuroscience Letters. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Dormer A et al. A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials. Journal of Pain Research. 2023. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Brenn D et al. Erythromelalgia caused by the missense mutation p.Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7). European Journal of Pain. 2024. ↩︎ ↩︎